|
|
Vol. 17.18 – 02 October, 2026
|
|
|
|
|
|
|
|
|
Researchers integrated multi-omics analyses of resistant models and patient specimens, identifying glutathione S-transferase alpha 4 (GSTA4) as a pivotal ferroptosis suppressor that drives antiandrogen resistance in CRPC. [Advanced Science]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists identified enhancer of zeste homolog 2 (EZH2)-PI3K/mTORC1 signaling as a therapeutic vulnerability in phenotypically plastic prostate cancer and revealed tristetraprolin (TTP)-associated regulatory programs as contributors to targeted therapy response.
[Cell Reports Medicine]
|
|
|
|
|
|
The authors identified follistatin, a TGFβ superfamily antagonist, as a key driver of androgen receptor (AR)-independence and treatment resistance in prostate cancer.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
Researchers investigated whether the frequently amplified chromatin effector pygopus 2 (PYGO2) regulates lymphoid organization and antitumor immunity in prostate cancer.
[Cancer Letters]
|
|
|
|
|
|
Investigators assessed the clinical relevance and inclusivity of 46 prostate cancer cell lines using an integrated clinical and multiomics approach.
[Communications Medicine]
|
|
|
|
|
|
Scientists integrated human prostate cancer specimens, single-cell RNA-sequencing datasets, a prostate-specific Pten conditional knockout mouse model, mouse single-cell transcriptomics, and mechanistic in vitro experiments to investigate senescence and stromal remodeling.
[Neoplasia]
|
|
|
|
|
|
The authors investigated how physiologically relevant mechanical properties affect prostate cancer cells using 2D-poly(dimethylsiloxane) and topographic 2.5D-poly(ethylene glycol) diacrylate-glycidyl methacrylate hydrogel surfaces.
[iScience]
|
|
|
|
|
|
Researchers investigated whether transient receptor potential melastatin 4 (TRPM4) expression defines Acetalax sensitivity in prostate cancer, comparing TRPM4-high and -low prostate cancer cell lines.
[Molecular Cancer Therapeutics]
|
|
|
|
|
|
The authors suggested that benzopyrene could contribute to the acquisition of pro-invasive phenotypes in prostate epithelial cells and potentially to prostate carcinogenesis, probably through upregulating PTP4A3 to activate matrix remodeling programs.
[Chemico-Biological Interactions]
|
|
|
|
|
|
Researchers investigated the metabolomic profiles and preliminary anticancer activity of methanolic extracts from two Red Sea sponge species, Liosina granularis and Callyspongia crassa, using prostate and ovarian cancer cell models.
[Scientific Reports]
|
|
|
|
|
|
Investigators identified aurora kinase A (AURKA) as a key regulator of global DNA methylation in prostate cancer cells. AURKA depletion markedly reduces genomic 5-methylcytosine levels.
[Epigenetics]
|
|
|
|
|
|
Scientists assessed the anti-proliferative effects of matrine in multiple prostate cancer cell lines using CCK-8, EdU, and colony formation assays. [Experimental Cell Research]
|
|
|
|
|
|
|
|
The authors propose a spatiotemporal coevolution paradigm, wherein resistance in CRPC emerges not through linear genetic selection alone but through dynamic, reciprocal interactions among tumor cells, stromal components, and immune populations across both temporal and spatial dimensions. [International Journal of Molecular Medicine]
|
|
|
|
|
|
Scientists synthesize mechanistic, translational, and clinical evidence and organize it by cellular compartment, treatment-associated immune state, clinical trial strategy, and biomarker readiness for metastatic CRPC. [The Prostate]
|
|
|
|
|
|
|
|
The Prostate Cancer Foundation will convene leading researchers, clinicians and industry experts at its 33rd Annual Scientific Retreat. The Retreat is the world’s foremost scientific conference on prostate cancer biology and treatment.
[Prostate Cancer Foundation (BusinessWire)]
|
|
|
|
|
|
A new seed-grant fund established in collaboration with Renown Health’s William N. Pennington Cancer Institute has awarded more than $667,000 to researchers, including Dr. Dean Burkin to study a small molecule which could be useful as a treatment modality for prostate cancer.
[Nevada Today]
|
|
|
|
|
|
Weill Cornell Medicine has received major new funding to support collaborative research, including a $2 million grant to Dr. Scott Tagawa from the Department of Defense to lead Weill Cornell Medicine and NewYork-Presbyterian’s participation in the Prostate Cancer Clinical Trials Consortium. [Weill Cornell Medicine]
|
|
|
|
|
|
|
|
November 16-17, 2026 Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
|
|
|
|
Mayo Clinic – Phoenix, Arizona, United States
|
|
|
|
|
|
|
La Jolla Institute for Immunology – San Diego, California, United States
|
|
|
|
|
|
|
Columbia University Irving Medical Center – New York City, New York, United States
|
|
|
|
|
|
|
VIB Center for Cancer Biology – Leuven, Belgium
|
|
|
|
|
|
|
University of Gothenburg – Gothenburg, Sweden
|
|
|
|
|
|